In this open-label, prospective clinical trial, the investigators enrolled acute myeloid
leukemia (AML) patients after consolidation therapy. Patients with minimal residual disease
(MRD) receive decitabine treatment if patients do not receive stem cell transplantation. The
MRD clearance rate is the primary outcome to measure the efficacy of decitabine regimen.